ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY A. Maiolino; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA D.S. Siegel; K. Weisel; A. Zahlten-Kumeli; R. Medhekar; S. Sapra; B. Ding; X. Leleu;

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS M.E.Z. Capra; M. Beksac; P.G. Richardson; A. Unal; P. Corradini; S. Delimpasi; Z. Gulbas; G. Mikala; A. Neylon; A. Symeonidis; S. Bringhen; P. Moreau; H.V. Velde; F. Campana; S.L. Guennec; I. Spicka;